Interações de Carbidopa + levodopa + entacapona

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (bula de Carbidopa + levodopa + entacapona, Contraindicações)

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. (bula de Carbidopa, Contraindicações)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (bula de Carbidopa + levodopa + entacapona, Contraindicações)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (bula de Carbidopa + levodopa + entacapona, Contraindicações)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (bula de Carbidopa + levodopa + entacapona, Contraindicações)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (bula de Carbidopa + levodopa + entacapona, Contraindicações)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (bula de Carbidopa + levodopa + entacapona, Contraindicações)

WARNING Because of the risk of potentially fatal, acute fulminant liver failure, Tolcapone tablets should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies (see INDICATIONS and DOSAGE AND… (bula de Tolcapona, Advertência em caixa preta)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (bula de Carbidopa + levodopa + entacapona, Contraindicações)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Hypotension, orthostatic hypotension, and syncope are observed in patients treated with drugs that increase central dopaminergic tone including Carbidopa, levodopa and entacapone tablets. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Hypotension, orthostatic hypotension, and syncope are observed in patients treated with drugs that increase central dopaminergic tone including Carbidopa, levodopa and entacapone tablets. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Carbidopa, levodopa and entacapone tablets ( 7.5 , 7.6 , 7.7 , 7.8 , 7.9 ) • Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Carbidopa, levodopa and entacapone tablets may be required (… (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

• Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Carbidopa, levodopa and entacapone tablets ( 7.5 , 7.6 , 7.7 , 7.8 , 7.9 ) • Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Carbidopa, levodopa and entacapone tablets may be required (… (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Carbidopa, levodopa and entacapone tablets ( 7.5 , 7.6 , 7.7 , 7.8 , 7.9 ) • Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Carbidopa, levodopa and entacapone tablets may be required (… (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. (bula de Droxidopa, Advertências e precauções)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Because patients may not recognize these behaviors as abnormal it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending or other urges while being treated with entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Carbidopa, levodopa and entacapone tablets ( 7.5 , 7.6 , 7.7 , 7.8 , 7.9 ) • Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Carbidopa, levodopa and entacapone tablets may be required (… (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Carbidopa, levodopa and entacapone tablets ( 7.5 , 7.6 , 7.7 , 7.8 , 7.9 ) • Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Carbidopa, levodopa and entacapone tablets may be required (… (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Dopamine D2 Receptor Antagonists Dopamine D2 receptor antagonists (e.g., metoclopramide, phenothiazines, butyrophenones, risperidone) may reduce the therapeutic effects of levodopa. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

• Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Carbidopa, levodopa and entacapone tablets ( 7.5 , 7.6 , 7.7 , 7.8 , 7.9 ) • Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Carbidopa, levodopa and entacapone tablets may be required (… (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Hypotension, orthostatic hypotension, and syncope are observed in patients treated with drugs that increase central dopaminergic tone including Carbidopa, levodopa and entacapone tablets. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Dopamine D2 Receptor Antagonists Dopamine D2 receptor antagonists (e.g., metoclopramide, phenothiazines, butyrophenones, risperidone) may reduce the therapeutic effects of levodopa. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Hypotension, orthostatic hypotension, and syncope are observed in patients treated with drugs that increase central dopaminergic tone including Carbidopa, levodopa and entacapone tablets. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Interaction with Levodopa : Seizures, over-stimulation or irritability may occur; monitor patients for a change in neurologic status. (bula de Sapropterina, Advertências e precauções)

Interaction with Levodopa : Seizures, over-stimulation or irritability may occur; monitor patients for a change in neurologic status. (bula de Sepiapterina, Advertências e precauções)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Drugs that Increase Blood Pressure and/or Heart Rate and Dopaminergic Drugs : Use caution when co-administering with SUNOSI. (bula de Solriamfetol, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission [see Drug Interactions (7.6) ]. (bula de Tetrabenazina, Advertências e precauções)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (bula de Triexifenidil, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Valbenazina, Advertências e precauções)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of Carbidopa, levodopa and entacapone tablets may be required; monitor INR when initiating Carbidopa, levodopa and entacapone tablets in patients on coumadin ( 7.11 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

The expected incidence of fibrotic complications is so low that even if entacapone caused these complications at rates similar to those attributable to other dopaminergic therapies, it is unlikely that it would have been detected in a cohort of the size exposed to entacapone during its clinical development. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

The expected incidence of fibrotic complications is so low that even if entacapone caused these complications at rates similar to those attributable to other dopaminergic therapies, it is unlikely that it would have been detected in a cohort of the size exposed to entacapone during its clinical development. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have been reported in some patients treated with ergot derived dopaminergic agents. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have been reported in some patients treated with ergot derived dopaminergic agents. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

The expected incidence of fibrotic complications is so low that even if entacapone caused these complications at rates similar to those attributable to other dopaminergic therapies, it is unlikely that it would have been detected in a cohort of the size exposed to entacapone during its clinical development. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening have been reported in some patients treated with ergot derived dopaminergic agents. (bula de Carbidopa + levodopa + entacapona, Advertências e precauções)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol). (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)